表紙
市場調查報告書
商品編碼
1043943

全球製藥業的增長機會

Global Pharmaceutical Industry Growth Opportunities

出版日期: | 出版商: Frost & Sullivan | 英文 46 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告探討了全球製藥行業的增長機會,分析了 2021 年的亮點、對 2022 年及以後的預測、增長動力和限制、合同和交易,以及有關法規、贖回和政策的最新信息。它提供了信息例如 FDA 對新藥的主要批准。

目錄

戰略義務

增長機會宇宙

  • 製藥:影響增長的因素
  • 全球醫藥行業增長機會分析
  • 2021 年的亮點和 2022 年的預期
  • 生長促進劑
  • 生長抑製劑
  • 市場快照:下一代生物形態模式
  • FDA 對新藥的主要批准
  • FDA 對新藥的主要批准:要點
  • 重大併購交易
  • 醫藥行業重大併購交易:重點
  • 主要產品許可合同
  • 主要產品許可合同:要點
  • 主要數字合作交易
  • 主要數字合作交易:要點
  • 主要監管、贖回和政策更新
  • 主要法規、兌換和政策更新:要點

增長機會宇宙

  • 增長機會1:改變研發生產力的新藥模式和RNA治療
  • 增長機會2:整合RWE支持藥物開發平台/解決方案,提升用戶體驗
  • 圖表列表
  • 免責聲明
目錄
Product Code: MG4D-52

2021 Highlights and What to Expect in 2022

The global pharmaceutical industry is witnessing dynamic trends following the coronavirus pandemic and is adapting to new challenges and opportunities. This study analyzes the 2021 highlights in the global pharmaceutical industry and provides forecasts for the next year and beyond.

It addresses the impact of innovative modalities, technologies, and recent drug approvals, such as gene and cell therapy, monoclonal antibodies,

RNA-based therapeutics, and the increasing use of health data through real-world evidence and artificial intelligence. The need to gain access to early-stage drugs and novel technologies has led to a higher rate of licensing and mergers with small biopharma that are developing the same. In addition, patient engagement has been driving digital partnerships centered around digital therapeutics, decentralized clinical trials, remote monitoring, and telemedicine.

The study also provides critical insights into the key regulatory, reimbursement, and policy updates for 2021, ranging from health data standardization and quality regulation to direct drug pricing negotiations and biosimilars & generics encouragement.

Table of Contents

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Strategic Imperative 8™ on the Pharmaceuticals Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Universe

  • Pharmaceuticals-Factors Affecting Growth
  • Growth Opportunity Analysis for the Global Pharmaceutical Industry
  • 2021 Highlights and What to Expect in 2022
  • 2021 Highlights and What to Expect in 2022 (continued)
  • 2021 Highlights and What to Expect in 2022 (continued)
  • Growth Drivers
  • Growth Restraints
  • Market Snapshot-Next-generation Biologics Modalities
  • Key FDA Approvals for Novel Drugs
  • Key FDA Approvals for Novel Drugs (continued)
  • Key FDA Approvals for Novel Drugs (continued)
  • Key FDA Approvals for Novel Drugs (continued)
  • Key FDA Approvals for Novel Drugs-Takeaways
  • Key M&A Deals
  • Key M&A Deals in the Pharma Industry-Takeaways
  • Key Product Licensing Deals
  • Key Product Licensing Deals (continued)
  • Key Product Licensing Deals (continued)
  • Key Product Licensing Deals-Takeaways
  • Key Digital Partnership Deals
  • Key Digital Partnership Deals (continued)
  • Key Digital Partnership Deals-Key Takeaways
  • Key Digital Partnership Deals-Key Takeaways (continued)
  • Key Regulatory, Reimbursement, and Policy Updates
  • Key Regulatory, Reimbursement, and Policy Updates (continued)
  • Key Regulatory, Reimbursement, and Policy Updates (continued)
  • Key Regulatory, Reimbursement, and Policy Updates (continued)
  • Key Regulatory, Reimbursement, and Policy Updates (continued)
  • Key Regulatory, Reimbursement, and Policy Updates (continued)
  • Key Regulatory, Reimbursement, and Policy Updates-Takeaways

Growth Opportunity Universe

  • Growth Opportunity 1: Novel Drug Modalities and RNA Therapeutics Transforming R&D Productivity
  • Growth Opportunity 1: Novel Drug Modalities and RNA Therapeutics Transforming R&D Productivity (continued)
  • Growth Opportunity 2: Integrated and RWE-supported Drug Development Platforms/Solutions to Improve User Experience
  • Growth Opportunity 2: Integrated and RWE-supported Drug Development Platforms/Solutions to Improve User Experience (continued)
  • List of Exhibits
  • Legal Disclaimer